
AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.
The company's adjusted EPADS reached $1.08, missing the consensus of $1.10. The adjusted EPS was $2.17 (1 ADR = 2 Common Shares).